Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Duodopa | Levodopa / carbidopa | Parkinson's disease | Do not list | Complete | ||
Fosavance 70/5600 | Alendronate sodium / cholecalciferol | Osteoporosis | List in a similar manner to other drugs in class | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis, glucocorticoid induced | Do not list | Complete | ||
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
Olmetec Plus | Olmesartan medoxomil + hydrochlorothiazide | Hypertension | List in a similar manner to other drugs in class | Complete | ||
Olmetec | Olmesartan medoxomil | Hypertension | List in a similar manner to other drugs in class | Complete | ||
Viread | Tenofovir disoproxil fumarate | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | ||
Enablex | Darifenacin hydrobromide | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
Remicade | Infliximab | Ulcerative Colitis | Do not list | Complete | ||
Apidra | Insulin glulisine | Diabetes, Mellitus (Type 1 & 2) | List in a similar manner to other drugs in class | Complete |